Fineline Cube

Follow:
14499 Articles
Changchun Pharma Wins FDA Approval for GenSci128 in TP53 Y220C Solid Tumors
CompanyDrug

Changchun Pharma Wins FDA Approval for GenSci128 in TP53 Y220C Solid Tumors

Yantai Dongcheng Pharma Gains NMPA Approval for Sodium Fluoride [18F]
CompanyDrug

Yantai Dongcheng Pharma Gains NMPA Approval for Sodium Fluoride [18F]

Explore the latest insights on Yaohua Medical Instrument and its impact on China's pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Yaohua Medical Instrument's developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.
CompanyDeals

Guided Therapeutics Receives Payment from Shandong Yaohua for LuViva Commercialization

RemeGen's Telitacicept Approved for Myasthenia Gravis in China
CompanyDrug

RemeGen’s Telitacicept Approved for Myasthenia Gravis in China

Biogen and City Therapeutics Collaborate on RNAi Therapies for CNS Diseases
CompanyDeals

Biogen and City Therapeutics Collaborate on RNAi Therapies for CNS Diseases

HKSH Medical Partners with United Imaging to Advance CT Technology
CompanyDeals

HKSH Medical Partners with United Imaging to Advance CT Technology

AstraZeneca's Imfinzi Gets Positive Opinion for Bladder Cancer Perioperative Treatment
CompanyDrug

AstraZeneca’s Imfinzi Gets Positive Opinion for Bladder Cancer Perioperative Treatment

EyePoint's Partner Betta Completes Enrollment for Duravyu's Pivotal Phase III Study
CompanyDrug

EyePoint’s Partner Betta Completes Enrollment for Duravyu’s Pivotal Phase III Study

EMA Recommends Tevimbra for Nasopharyngeal Cancer First-line Treatment
CompanyDrug

EMA Recommends Tevimbra for Nasopharyngeal Cancer First-line Treatment

AbelZeta Pharma's C-CAR168 Secures FDA RMAT Designation for Lupus Treatments
CompanyDrug

AbelZeta Pharma’s C-CAR168 Secures FDA RMAT Designation for Lupus Treatments

FDA Rejects Data from Two Chinese Testing Labs Over Compliance Concerns
Policy / Regulatory

FDA Rejects Data from Two Chinese Testing Labs Over Compliance Concerns

CARsgen's Satricabtagene Autoleucel Granted Priority Review by China's CDE
CompanyDrug

CARsgen’s Satricabtagene Autoleucel Granted Priority Review by China’s CDE